Department of Experimental Physiology, Medical School, National and Kapodistrian University of Athens, Athens, 75 Micras Asias, Goudi-Athens, 115 27, Greece.
Department of Experimental Physiology, Medical School, National and Kapodistrian University of Athens, Athens, 75 Micras Asias, Goudi-Athens, 115 27, Greece.
Mutat Res Rev Mutat Res. 2017 Apr-Jun;772:105-122. doi: 10.1016/j.mrrev.2016.09.005. Epub 2016 Sep 19.
The insulin-like growth factors (IGFs) system regulates cell growth, differentiation and energy metabolism and plays crucial role in the regulation of key aspects of tumor biology, such as cancer cell growth, survival, transformation and invasion. The current focus for cancer therapeutic approaches have shifted from the conventional treatments towards the targeted therapies and the IGF system has gained a great interest as anti-cancer therapy. The proliferative, anti-apoptotic and transformation effects of IGFs are mainly triggered by the ligation of the type I IGF receptor (IGF-IR). Thus, aiming at developing novel and effective cancer therapies, different strategies have been employed to target IGF system in human malignancies, including but not limited to ligand or receptor neutralizing antibodies and IGF-IR signaling inhibitors. In this review, we have focused on the clinical studies that have been conducted targeting the various components of the IGF system for the treatment of different types of cancer, providing a description and the challenges of each targeting strategy and the degree of success.
胰岛素样生长因子 (IGFs) 系统调节细胞生长、分化和能量代谢，在肿瘤生物学的关键方面（如癌细胞生长、存活、转化和侵袭）的调控中发挥着至关重要的作用。目前，癌症治疗方法的重点已经从传统治疗转向靶向治疗，而 IGF 系统作为抗癌治疗已经引起了极大的兴趣。IGFs 的增殖、抗凋亡和转化作用主要是通过 IGF-IR 的配体结合触发的。因此，为了开发新型有效的癌症治疗方法，已经采用了不同的策略来靶向人类恶性肿瘤中的 IGF 系统，包括但不限于配体或受体中和抗体和 IGF-IR 信号抑制剂。在这篇综述中，我们重点介绍了针对 IGF 系统的各种成分进行的临床研究，以治疗不同类型的癌症，描述和挑战每种靶向策略以及成功程度。
